摘要
Hepatocellular carcinoma (HCC) is the third leading cause of cancer-related death attributed to high fre-quency of metastasis and multiple drug resistance. We aim to examine the underlying molecular mechanism and to seek potential strategies to reverse primary/acquired resistance to regorafenib. Topoisomerase II alpha (TOP2A) is criti-cal for tumorigenesis and carcinogenesis. Clinically, high-TOP2A expression was correlated to shorter overall survival (OS) of patients, but its role in drug resistance of HCC remains unknown. Here, we screened the expression profiling of TOP2A in HCC and identified TOP2A as an upregulated gene involved in the resistance to regorafenib. Sustained exposure of HCC cells to regorafenib could upregulate the expression of TOP2A. Silencing TOP2A enhanced HCC cells' sensitivity to regorafenib. TOP2A inhibition by doxorubicin or epirubicin synergized with regorafenib to sup-press the growth of sorafenib-resistant HCC tumors that possessed the sorafenib-resistant features both in vitro and in vivo. Thus, targeting TOP2A may be a promising therapeutic strategy to alleviate resistance to regorafenib and thus improving the efficacy of HCC treatment.
学科与关键词
- Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expressionFu, Rongdang; Jiang, Shaotao; Li, Jieyuan; Chen, Huanwei*; Zhang, Xiaohong*MEDICAL ONCOLOGY, 2020, 37(4): 24.被引 62
- Linc-ROR drive adriamycin resistance by targeting AP-2α/Wnt/β-catenin axis in hepatocellular carcinomaShi, Chuan-Jian; Lv, Min-Yi; Deng, Li-Qiang; Zeng, Wei-Qiang; Fu, Wei-Ming*; Zhang, Jin-Fang*Cell Biology and Toxicology, 2023, 39(4): 1735-1752.被引 1
- Fucoidan inhibits EGFR redistribution and potentiates sorafenib to overcome sorafenib-resistant hepatocellular carcinomaLuo, Jialiang; Li, Lei; Zhu, Zhengyumeng; Chang, Bo; Deng, Fan; Wang, Di; Lu, Xiao; Zuo, Daming; Chen, Qingyun*; Zhou, Jia*Biomedicine and Pharmacotherapy, 2022, 154: 113602.被引 8
